Jaunmuktane et al. [4] present a series of four patients who underwent neurosurgical procedures during childhood or teenage years and presented with intracerebral haemorrhage approximately 3 decades later caused by severe cerebral amyloid angiopathy (CAA). They show that none carried pathogenic mutations associated with early Aβ pathology development. They also identified four patients from the literature with a history of neurosurgical intervention and subsequent development of CAA. The small number of patients selected from a large volume neurosurgical centre collected over 14 years (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) raises the possibility of a, necessarily, highly selected patient cohort with a high risk of bias particularly in the context of a national neuroscience centre that collates rare, complex and unusual pathology. The number of patients undergoing neurosurgical procedures in this centre is not quantified as a possible denominator although it appears two of the patients did not undergo their neurosurgical procedures in the UK. The underlying neurosurgical pathologies are diverse and raise the possibility of additional factors such as trauma-related amyloid beta deposition [5] and radiation-induced amyloid deposition [10] as credible alternative possibilities. We are, therefore, concerned that the evidence is circumstantial and care must be taken in drawing the firm conclusions stated in the paper from small numbers of cases in an apparently rare pathology. Nevertheless, we acknowledge that the authors raise the possibility that Aβ pathology may be transmissible as a proteopathic protein, akin to prion disease, through neurosurgical procedures.
As the society representing British Neurosurgery, we welcome research which assists us in delivering safe and effective neurosurgical treatment for patients. This study raises an interesting and potentially important relationship that Aβ pathology is transmissible by surgical instruments. It needs to be stressed, however, that there are enormous difficulties in terms of proving this hypothesis with the current extremely limited evidence due to a number of factors including miniature sample size, retrospective data collection and significant selection bias in relation to controls. It would be important to clarify the incidence of CAA in a large sample of young patients without genetic risk factors or a history of neurosurgery.
As neurosurgeons, we are acutely aware that the likelihood of death or disability from many of the neurological and neurosurgical conditions that we treat is high, as is the risk of the neurosurgery used to treat them. The decision to explore the benefits of neurosurgery is often a delicate balance between the natural history of the disease versus the very real risks and consequences of intervention. On current evidence, least among these risks or consequences is the likelihood of iatrogenic infection from contaminated instruments. The authors also allude to the use of disposable instruments; however, there are well-defined deficiencies of disposable instruments particularly in relation to microsurgery, which in itself carries a technical surgical risk.
From the currently available evidence, it would appear that standard decontamination and sterilisation practices are sufficient to cleanse neurosurgical instruments and protect subsequent patients against disease transmission of amyloid angiopathy. It is recognised that proteopathic proteins may adhere to instruments and be resistant to standard methods of sterilisation. The most concerning of these proteopathic diseases is Creutzfeldt-Jakob Disease (CJD). There have been a small number of cases in the past due to neurosurgical procedures, and larger numbers following unintentional implantation of contaminated human graft materials and use of human hormone preparations. Each of these events has been followed by rigorous Government and Clinical responses to limit the risks.
With the emergence of variant CJD (vCJD) in the UK during the 1990s, these efforts were redoubled, theoretical modelling was undertaken by the National Institute of Clinical Excellence (NICE) and policies were put in place to limit the likelihood of this becoming a population decimating self-sustaining iatrogenic epidemic. Given that iatrogenic CJD can have incubation times of up to 4 decades [9] and can be clinically and pathologically identical to sporadic CJD, thus disguising any possible origin from a transmitted pathogen [8] , this risk is very difficult to quantify and to date no iatrogenic cases of vCJD have been reported as a result of surgical interventions. However, transmission by blood transfusion has occurred and we must remain vigilant.
Two important parallels can be drawn with the current study. First, CAA (28-38% of elderly brains [6] ) is a much more common pathology than CJD (1-2 per million affected by prion disease worldwide [2] and 176 cases of new variant CJD in the UK between 1994 and 2011 in total [1] ). If Jaunmuktane et al. hypothesise that amyloid beta is a proteopathic protein, its infectivity must be several orders of magnitude less than prion disease based on these relative incidences and the rarity of CAA in patients under the age of 55, despite several decades of neurosurgery in the paediatric population (1660 paediatric shunt operations alone in the UK each year [7] ). Second, a distinction between the use of instruments which are transiently in contact with neural tissue and human-derived infected implants which are left within the skull needs to be recognised as a potential risk factor. We note the paper by Herve et al. [3] describing fatal Abeta cerebral amyloid angiopathy 4 decades after a dural graft at the age of 2 years.
Evidence continues to accumulate about the potential transmissible nature of neurodegenerative diseases, including Alzheimer's and Parkinson's disease, and now CAA. However, the risks of developing one of these degenerative diseases as a consequence of neurosurgery on current evidence seems substantially smaller than the everyday risks of the procedures themselves and the diseases they are used to treat.
In terms of reducing the risk it is recognised that prion proteins have an affinity for stainless steel and if instruments are allowed to dry may become fixed and more difficult to cleanse. Keeping those instruments exposed to high-risk tissues wet allows more effective decontamination, and efforts have been made to develop agents that denature these proteins during the sterilisation process. The move away from at-point-of-use sterilisation towards centralised systems has allowed standardisation and more rigorous quality control of instrument processing, although this remains variable. Currently, however, none of these approaches is sufficiently reliable or practical to offer the hope expressed in NICE IPG196 that a technological answer to this problem might be on the horizon.
We welcome larger studies of a multidisciplinary nature to include pathologists, physicians, surgeons, epidemiologists, statisticians, instrument manufacturers, charities representing patients and other patient public involvement. These studies will be challenging given the substantial incubation times. In the meantime, NICE is currently working in collaboration with NHS England and the Society of British Neurological Surgeons to update its guidance to take account of the evolving understanding of these diseases and their prevention.
